Syndromic Multiplex Diagnostic Global Market Report 2023: Speed of Diagnosis and Lower Costs Drive Adoption
05 janv. 2023 08h48 HE
|
Research and Markets
Dublin, Jan. 05, 2023 (GLOBE NEWSWIRE) -- The "Syndromic Multiplex Diagnostic Markets with COVID-19 Impacts. Strategies and Trends, Forecasts by Syndrome (Respiratory, Sepsis, GI Etc.), by Country,...
Two Female Scientists Win this year’s King Faisal Prize
04 janv. 2023 13h57 HE
|
King Faisal Prize
Jeddah, Saudi Arabia, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Two women scientists were announced King Faisal Prize for Medicine and Science laureates for 2023: a Covid-19 vaccine developer and a...
OTC/DTC Infectious Disease Diagnostics Market Report 2023: New Sampling Technology and Rapid and Multiplex Tests Present Opportunities
04 janv. 2023 07h03 HE
|
Research and Markets
Dublin, Jan. 04, 2023 (GLOBE NEWSWIRE) -- The "OTC/DTC Infectious Disease Diagnostics Strategies and Trends, COVID-19 Adjusted Forecasts: by Application, by Channel, by Country. With Market...
Assembly Biosciences Announces Promising Interim Results from Two Clinical Trials Evaluating Highly Potent Next-Generation Core Inhibitor Candidates ABI-H3733 and ABI-4334
19 déc. 2022 08h00 HE
|
Assembly Biosciences, Inc.
In initial ABI-H3733 cohort of 50 mg in 28-day Phase 1b study, six of eight HBV patients on treatment reached lower limit of quantification for HBV DNA by day 21 and patients showed a mean reduction...
Provectus Biopharmaceuticals Announces Decision to Not Undertake Reverse Split of Outstanding and Authorized Equities in 2022; Expects to Seek Same Stockholder Approval Again in 2023
12 déc. 2022 08h00 HE
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the Company’s Board of Directors (Board) has decided to not undertake the reverse stock split and...
Assembly Biosciences Reports Third Quarter 2022 Financial Results and Recent Highlights and Announces Upcoming Conference Participation
08 nov. 2022 16h05 HE
|
Assembly Biosciences, Inc.
Phase 1a Trial of Next-Generation Core Inhibitor, ABI-4334, Now Underway Following Clinical Trial Application (CTA) Clearance SOUTH SAN FRANCISCO, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Assembly...
Virology Specimen Collection Global Market to Reach $6.76 Billion by 2026 at a CAGR of 4%
04 nov. 2022 09h18 HE
|
Research and Markets
Dublin, Nov. 04, 2022 (GLOBE NEWSWIRE) -- The "Virology Specimen Collection Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.The global virology specimen...
Virology Market Growing Demands, 2022 | Latest Innovations, Industry Size-Share, Key Development Trends, Market Performance, Product Situation, Growth Opportunities, Competitive Situation, and Future Market Outlook Till 2028
01 sept. 2022 08h38 HE
|
Industry Research
Pune, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Global “Virology Market” 2022-2028 report discovers comprehensive insights on key manufacturers with share information, market size and projection, key...
Insights on the Bioanalytical Testing Services Global Market to 2027 - Emerging Countries in the Asia Pacific Region Present Opportunities
12 août 2022 04h28 HE
|
Research and Markets
Dublin, Aug. 12, 2022 (GLOBE NEWSWIRE) -- The "Global Bioanalytical Testing Services Market (2022-2027) by Type, Application, End-User, Geography, Competitive Analysis and the Impact of Covid-19...
Provectus Biopharmaceuticals Announces Stockholder Approval to Undertake Reverse Split of Outstanding Equities and Reduce Number of Authorized Equities by Same Ratio
23 juin 2022 09h41 HE
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, June 23, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the Company’s shareholders have approved the proposals of Provectus’ Board of Directors (Board) to seek...